Ivantis, based in Irvine, CA, is a leading provider of innovative ophthalmic devices, specializing in the development of the Hydrus Microstent for the treatment of mild to moderate primary open-angle glaucoma. Their revolutionary canal-based MIGS device offers a unique mechanism of action, providing long-term safety and effectiveness outcomes as demonstrated in pivotal trials.
The Hydrus Microstent, roughly the size of an eyelash, is designed to bypass the trabecular meshwork and restore the flow of aqueous humor, offering a gold standard treatment option for patients with glaucoma. With a strong recommendation and moderate quality data rating, the Hydrus Microstent has established itself as a reliable choice for eye care professionals seeking efficient and confident microstent delivery.
Generated from the website